Abbott Laboratories 株価情報 (NYSE: ABT)

最新ニュース Abbott Laboratories (NYSE:ABT) 株価情報

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Arcblock - United States Dollar

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

The U.S. Food and Drug Administration announced a ban on Red No. 3, an artificial food coloring linked to cancer in animal studies, effective Jan. 15, 2027. 
The dye, found in products ranging from candy to cold medicine, has been scrutinized for decades. This move follows the FDA's 1990 prohibition of the dye in cosmetics due to its carcinogenic <a href="https://www.benzinga.com/fda-calendar">effects on lab rats</a>.
The decision, announced on Wednesday, comes in response to a 2022 petition by consumer advocacy groups, including Consumer Reports, Public Citizen and the Environmental Working Group, urging the FDA to eliminate Red No. 3 from the American diet. The agency acknowledged the dye induces cancer in male rats and is subject to the Delaney Clause, a regulation banning substances shown to cause cancer in humans or animals from being used in food.
"Red Dye 3 poses an unacceptable risk to our health, especially when safer alternatives are readily available," said Brian Ronholm, director of food policy at Consumer Reports, <a href="https://www.bloomberg.com/news/articles/2025-01-15/us-fda-to-ban-red-dye-no-3-rfk-went-after-due-to-cancer-link?srnd=homepage-americas&amp;sref=TBDibEcD">as reported</a> by Bloomberg. Advocacy groups have argued that banning the dye will encourage manufacturers to adopt safer ingredients already in use in Europe and other countries.
<h1 class="wp-block-heading">Children's Products Loaded With Red Dye No. 3</h1>
The dye, widely prevalent in U.S. supermarkets, seems to be especially used to color food items consumed by young children. An analysis by the healthy food app <a href="https://www.gococo.app/">GoCoCo</a> revealed its presence in 26% of baking decorations, 16% of chewing gum, 13% of candy and 11% of cookies. 
Products such as Brach's candy corn produced by the Ferrara Candy Co., Betty Crocker sprinkles made by General Mills Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) and strawberry Ensure from Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) contain Red dye No 3. It is also used in medications, including Takeda Pharmaceutical Co. Ltd.&#8217;s (NYSE: TAK) Vyvanse, a medication used to treat attention deficit hyperactivity disorder, which <a href="https://www.cdc.gov/adhd/data/index.html#:~:text=Millions%20of%20U.S.%20children%20have%20been%20diagnosed%20with%20ADHD.&amp;text=An%20estimated%207%20million%20(11.4,parents%20using%20data%20from%202022.">affects</a> seven million U.S. children and teens.&nbsp;Store-brand heartburn remedies from Costco Wholesale Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cost#NASDAQ">COST</a>) and Rite Aid also contain Red dye No 3.
"If you can't put it on your skin why would you eat it?" said Linda Birnbaum, former director of the National Institute of Environmental Health Sciences and the National Toxicology Program, in an interview with Bloomberg last month. "Bright red dye is completely unessential. We don't need bright red candies."
The industry expressed support for the FDA's regulatory authority. "Our consumers and everyone in the food industry want and expect a strong FDA," the National Confectioners Association said in a statement.
Ferrara and General Mills have indicated their readiness to meet the new standards. Ferrara has already begun reformulating products.
While the ban marks progress, advocates like Scott Faber of the Environmental Working Group are urging the FDA to tackle other dyes, including Red No. 40 and Yellow Nos. 5 and 6, linked to hyperactivity and other health concerns.
Now Read: • <a href="https://www.benzinga.com/government/regulations/24/11/42144709/kennedys-war-on-food-dyes-could-be-coming-to-your-breakfast-table">Kennedy's War On Food Dyes Could Be Coming To Your Breakfast Table</a>
Photo: Shutterstock.

Equities

Government

News

Regulations

Health Care

Markets

COST

FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$25.00</td>
<td>$380.0K</td>
<td>2.3K</td>
<td>3.5K</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$115.00</td>
<td>$64.3K</td>
<td>26</td>
<td>3.0K</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$26.00</td>
<td>$48.1K</td>
<td>12.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>ONC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$180.00</td>
<td>$40.5K</td>
<td>0</td>
<td>406</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$145.00</td>
<td>$75.0K</td>
<td>39</td>
<td>302</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$175.00</td>
<td>$90.1K</td>
<td>7.2K</td>
<td>170</td>
</tr>
<tr>
<td>HROW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$35.00</td>
<td>$40.7K</td>
<td>203</td>
<td>167</td>
</tr>
<tr>
<td>OPCH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.00</td>
<td>$37.6K</td>
<td>208</td>
<td>157</td>
</tr>
<tr>
<td>PRAX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$55.00</td>
<td>$55.3K</td>
<td>421</td>
<td>154</td>
</tr>
<tr>
<td>MCK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$580.00</td>
<td>$30.6K</td>
<td>556</td>
<td>139</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a put option trade with neutral sentiment. It expires in 66 day(s) on March 21, 2025. Parties traded 1000 contract(s) at a $25.00 strike. The total cost received by the writing party (or parties) was $380.0K, with a price of $380.0 per contract. There were 2393 open contracts at this strike prior to today, and today 3522 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bullish sentiment. It expires in 213 day(s) on August 15, 2025. Parties traded 99 contract(s) at a $115.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $64.3K, with a price of $645.0 per contract. There were 26 open contracts at this strike prior to today, and today 3057 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with bullish sentiment. It expires in 38 day(s) on February 21, 2025. Parties traded 501 contract(s) at a $26.00 strike. This particular call needed to be split into 9 different trades to become filled. The total cost received by the writing party (or parties) was $48.1K, with a price of $96.0 per contract. There were 12780 open contracts at this strike prior to today, and today 1248 contract(s) were bought and sold. 
• Regarding ONC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>), we observe a put option sweep with bearish sentiment. It expires in 213 day(s) on August 15, 2025. Parties traded 33 contract(s) at a $180.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $40.5K, with a price of $1230.0 per contract. There were 0 open contracts at this strike prior to today, and today 406 contract(s) were bought and sold. 
• For BIIB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), we notice a call option sweep that happens to be bearish, expiring in 38 day(s) on February 21, 2025. This event was a transfer of 100 contract(s) at a $145.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $75.0K, with a price of $750.0 per contract. There were 39 open contracts at this strike prior to today, and today 302 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a put option sweep that happens to be bearish, expiring in 38 day(s) on February 21, 2025. This event was a transfer of 142 contract(s) at a $175.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $90.1K, with a price of $635.0 per contract. There were 7210 open contracts at this strike prior to today, and today 170 contract(s) were bought and sold. 
• Regarding HROW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), we observe a call option sweep with bullish sentiment. It expires in 38 day(s) on February 21, 2025. Parties traded 167 contract(s) at a $35.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $40.7K, with a price of $245.0 per contract. There were 203 open contracts at this strike prior to today, and today 167 contract(s) were bought and sold. 
• Regarding OPCH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>), we observe a call option sweep with bearish sentiment. It expires in 3 day(s) on January 17, 2025. Parties traded 47 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $37.6K, with a price of $801.0 per contract. There were 208 open contracts at this strike prior to today, and today 157 contract(s) were bought and sold. 
• Regarding PRAX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>), we observe a put option sweep with bullish sentiment. It expires in 38 day(s) on February 21, 2025. Parties traded 82 contract(s) at a $55.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $55.3K, with a price of $679.0 per contract. There were 421 open contracts at this strike prior to today, and today 154 contract(s) were bought and sold. 
• For MCK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), we notice a put option trade that happens to be bearish, expiring in 3 day(s) on January 17, 2025. This event was a transfer of 42 contract(s) at a $580.00 strike. The total cost received by the writing party (or parties) was $30.6K, with a price of $730.0 per contract. There were 556 open contracts at this strike prior to today, and today 139 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

BIIB

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HROW

OPCH

PRAX

10 Health Care Stocks With Whale Alerts In Today's Session

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$142.00</td>
<td>$132.6K</td>
<td>236</td>
<td>1.1K</td>
</tr>
<tr>
<td>CAPR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$15.00</td>
<td>$35.0K</td>
<td>3.7K</td>
<td>750</td>
</tr>
<tr>
<td>SOLV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$70.00</td>
<td>$25.0K</td>
<td>711</td>
<td>608</td>
</tr>
<tr>
<td>GEHC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$92.50</td>
<td>$83.4K</td>
<td>14</td>
<td>340</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$210.00</td>
<td>$87.3K</td>
<td>2.5K</td>
<td>284</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$45.00</td>
<td>$28.6K</td>
<td>53.7K</td>
<td>193</td>
</tr>
<tr>
<td>ABT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$110.00</td>
<td>$106.5K</td>
<td>210</td>
<td>101</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$220.00</td>
<td>$64.2K</td>
<td>184</td>
<td>20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a put option trade with neutral sentiment. It expires in 9 day(s) on January 17, 2025. Parties traded 829 contract(s) at a $142.00 strike. The total cost received by the writing party (or parties) was $132.6K, with a price of $160.0 per contract. There were 236 open contracts at this strike prior to today, and today 1103 contract(s) were bought and sold. 
• For CAPR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), we notice a put option sweep that happens to be bearish, expiring in 9 day(s) on January 17, 2025. This event was a transfer of 250 contract(s) at a $15.00 strike. This particular put needed to be split into 25 different trades to become filled. The total cost received by the writing party (or parties) was $35.0K, with a price of $140.0 per contract. There were 3727 open contracts at this strike prior to today, and today 750 contract(s) were bought and sold. 
• Regarding SOLV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOLV#NYSE">SOLV</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on January 17, 2025. Parties traded 100 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $250.0 per contract. There were 711 open contracts at this strike prior to today, and today 608 contract(s) were bought and sold. 
• For GEHC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), we notice a call option sweep that happens to be bearish, expiring in 254 day(s) on September 19, 2025. This event was a transfer of 139 contract(s) at a $92.50 strike. This particular call needed to be split into 18 different trades to become filled. The total cost received by the writing party (or parties) was $83.4K, with a price of $600.0 per contract. There were 14 open contracts at this strike prior to today, and today 340 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bullish sentiment. It expires in 373 day(s) on January 16, 2026. Parties traded 148 contract(s) at a $210.00 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $87.3K, with a price of $590.0 per contract. There were 2546 open contracts at this strike prior to today, and today 284 contract(s) were bought and sold. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option trade that happens to be bullish, expiring in 44 day(s) on February 21, 2025. This event was a transfer of 100 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $28.6K, with a price of $286.0 per contract. There were 53788 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding ABT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), we observe a call option sweep with bearish sentiment. It expires in 254 day(s) on September 19, 2025. Parties traded 101 contract(s) at a $110.00 strike. This particular call needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $106.5K, with a price of $1055.0 per contract. There were 210 open contracts at this strike prior to today, and today 101 contract(s) were bought and sold. 
• For VEEV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), we notice a call option trade that happens to be neutral, expiring in 373 day(s) on January 16, 2026. This event was a transfer of 20 contract(s) at a $220.00 strike. The total cost received by the writing party (or parties) was $64.2K, with a price of $3210.0 per contract. There were 184 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAPR

GEHC

SOLV

VEEV

8 Health Care Stocks Whale Activity In Today's Session

Barclays analyst Matt Miksic initiated coverage on Anteris Technologies Global Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVR#NASDAQ">AVR</a>) with a <a href="https://www.benzinga.com/quote/AVR/analyst-ratings" target="_blank" rel="noreferrer noopener">Positive rating and a forecast of $22</a>.
The analyst notes that Anteris Technologies&#8217; DurAVR valve system is expected to become the second balloon-expandable transcatheter valve replacement (BEV TAVR) system by 2028
Clinicians show a clear preference for BEV TAVR systems over self-expanding (SEV) systems from Medtronic plc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>).
The analyst points out that DurAVR, positioned as an emerging next-gen TAVR player, is on track to capture 4%-5% of the U.S. TAVR market by 2030.
Despite strong data from MDT in 2024, clinicians still favor balloon-expandable (BEV) TAVR systems, of which DurAVR is set to be the second.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression" rel="noreferrer noopener">Meta Drops Fact-Checking For Community Notes: Zuckerberg Sees &#8216;Opportunity To Restore Free Expression&#8217;</a>
The analyst estimates that in the U.S., around 130,000 isolated aortic valve replacement (AVR) procedures are performed annually, out of about 550,000 patients with symptomatic severe aortic stenosis (ssAS). Additionally, 175,000 new ssAS patients are diagnosed each year, while 100,000 patients die annually due to lack of treatment.
Although TAVR market growth has slowed, the analyst sees the market as underpenetrated and views it as a promising target for the next-gen DurAVR platform.
In addition to its BEV delivery system, DurAVR offers superior hemodynamics and laminar blood flow, combining the best features of leading TAVR platforms for more favorable hemodynamics and a low-profile valve height.
Early clinical evidence suggests that DurAVR could outperform other leading TAVR platforms in areas such as hemodynamics, outcomes in valve-in-valve (VIV) procedures and potentially in long-term durability, thanks to the company&#8217;s proprietary ADAPT tissue technology, Miksic writes.
For FY25, the analyst estimates the company to report a loss of $(1.30) per share.
Price Action: AVR shares are trading higher by 2.67% to $5.760&nbsp;at last check Tuesday.
Read now:
<ul>
<li><a href="https://www.benzinga.com/25/01/42830046/amd-reveals-new-ai-processors-gaming-products-ahead-of-ces-2025-shares-rise" target="_blank" rel="noreferrer noopener">AMD Unveils ‘Next Generation' AI Processors, Gaming Gear Ahead Of CES 2025</a></li>
</ul>
Anteris logo courtesy of company

Movers

General

Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has fallen 11.39% since its last report. The company recently reported that it has 12.10 million shares sold short, which is 0.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735587015_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 3.73%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About Abbott Laboratories?

<a href="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom" title="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom">https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom</a>

Biotech

DXCM

Abbott And DexCom Settle Global Patent Disputes Over Continuous Glucose Monitoring Products; Agreement Dismisses All Cases And Includes 10-Year Non-Litigation Provision With No Financial Payments

Alberta Government Adds Abbott Laboratories' Freestyle Libre 2 Flash Glucose Monitoring System To Alberta Drug Benefit List

Abbott Reports Completion Of In-human Leadless Left Bundle Branch Area Pacing  Procedures Using Investigational AVEIR CSP Leadless Pacemaker System

<ul>
<li>Dividend increased by 7.3%</li>
<li>Quarterly dividend payout has increased more than 60% since 2020</li>
<li>404th consecutive quarterly dividend to be paid by Abbott since 1924</li>
</ul>
ABBOTT PARK, Ill., Dec. 13, 2024 /PRNewswire/ -- Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) today announced that its board of directors has increased the company's quarterly common dividend to 59 cents per share, an increase of 7.3%. The company's quarterly dividend&nbsp;payout has increased more than 60% since 2020.

Dividends

Abbott Increases Quarterly Dividend From $0.55 To $0.59 Per Share

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Occidental Petroleum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) is one of his <a href="https://www.benzinga.com/quote/OXY/analyst-ratings">&#8220;least favorite oils.&#8221;</a>
On Monday, UBS analyst Josh Silverstein maintained Occidental Petroleum with a Neutral and lowered the price target from&nbsp;$58&nbsp;to&nbsp;$51, while Wells Fargo analyst Roger Read maintained the stock with an Equal-Weight and cut the price target from&nbsp;$56&nbsp;to&nbsp;$53.
&#8220;I think it's a very good situation,&#8221; Cramer said when asked about The Cooper Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COO#NYSE">COO</a>).
<ul>
<li><a href="https://analytics.google.com/analytics/web/#/p283071105/reports/explorer?params=_u..nav%3Dmaui%26_r..dataFilters%3D%5B%7B%22type%22:1,%22fieldName%22:%22landingPage%22,%22evaluationType%22:4,%22expressionList%22:%5B%22%252Ftrading-ideas%252Flong-ideas%252F24%252F04%252F38312296%252Fjim-cramer-recommends-buying-ethereum-or-bitcoin-instead-of-this-stock-lets-not-fool-aro%22%5D,%22complement%22:false,%22isCaseSensitive%22:true,%22expression%22:%22%22%7D%5D&amp;r=6342961161&amp;ruid=all-pages-and-screens,life-cycle,engagement&amp;collectionId=6114769606" target="_blank" rel="noreferrer noopener"></a></li>
</ul>
See Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38312296/jim-cramer-recommends-buying-ethereum-or-bitcoin-instead-of-this-stock-lets-not-fool-aro">Jim Cramer Recommends Buying Ethereum Or Bitcoin Instead Of This Stock: &#8216;Let&#8217;s Not Fool Around</a>
Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) is the &#8220;ultimate speculative, and as long as you know that, then I'm absolutely fine with it,&#8221; Cramer said.
Cramer recommended to keep owning Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>) and also recommended buying more in case it goes down.
The Mad Money host said he likes Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>). &#8220;I think that their legal stuff is really largely behind them,&#8221; he added.
When asked about Kinder Morgan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>), he said, &#8220;It's a good situation.&#8221;
As for Advanced Drainage Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMS#NYSE">WMS</a>), the company &#8220;missed the numbers by a mile,&#8221; Cramer said. &#8220;And when I see that, that often means that the next numbers' going to be missed too. So let's be careful there.&#8221;
Price Action:
<ul>
<li>Occidental Petroleum shares fell 0.9% to settle at $48.05 on Tuesday.</li>
<li>Cooper Companies shares fell 0.2% to close at $99.08.</li>
<li>Energy Transfer shares slipped 0.5% to settle at $18.74 on Tuesday.</li>
<li>Abbott shares gained 0.5% to $115.50 on Tuesday.</li>
<li>Kinder Morgan shares fell 0.8% to close at $26.89 on Tuesday.</li>
<li>Advanced Drainage Systems shares fell 1.7% to settle at $128.24 during the session.</li>
<li>Archer Aviation shares slipped 1.3% to close at $7.72 on Tuesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42429201/dow-falls-for-4th-straight-session-alphabet-surges-on-google-quantum-chip-announcement-fear-greed-index-remains-in-neutral-zone">Dow Falls For 4th Straight Session, Alphabet Surges On Google Quantum Chip Announcement: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

ACHR

Jim Cramer Says 'Keep Owning' This Energy Stock, Abbott Laboratories 'Legal Stuff' Is Behind Them

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has fallen 14.63% since its last report. The company recently reported that it has 12.05 million shares sold short, which is 0.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.15 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733495423_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 4.06%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into Abbott Laboratories's Recent Short Interest

Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating&nbsp;symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward Abbott's software-guided balloon-expandable TAVI system&nbsp;and is designed to build a foundation for artificial intelligence (AI) guided procedures. Once the investigational balloon-expandable system completes clinical development and is approved by regulatory authorities, Abbott's structural heart portfolio will offer physicians another TAVI management option to meet the patient's&nbsp;needs along with the company's Navitor&#x2122; TAVI system, which is already commercially available.
The aortic valve is a heart valve that controls the flow of oxygen-rich blood to the body. With age, calcium may build up in the valve and cause it to narrow – a condition known as aortic stenosis – resulting in the heart needing to work harder to pump blood through the valve. Left untreated, aortic stenosis can cause symptoms, such as chest pain, shortness of breath and fainting, and it can weaken the heart and become life-threatening. Patients who are at risk of open-heart surgery due to age, frailty or having multiple other conditions may benefit from minimally invasive treatment options where a device is delivered to the heart through an artery in the leg. Aortic stenosis remains the most common primary valve disease and its prevalence increases with age, ranging from approximately 2% in adults 70-80 years of age to 9% in adults older than 80 years.1
The investigational system is a type of balloon-expandable TAVI device, which works by crimping the new heart valve on a deflated balloon. The balloon with the mounted valve is then inserted into the body through an artery in the groin and routed up to the heart. Once properly positioned inside the narrowed heart valve, the balloon is inflated to expand the new valve, taking over the function of the patient's narrow native heart valve. The balloon is then deflated and removed from the body.

Abbott Tests New Balloon-Expandable TAVI System for Aortic Stenosis, Launches First Patient Procedures With Investigational TAVI Device

Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) (Insulet or the Company), the global leader in <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.omnipod.com%2F&amp;esheet=54155373&amp;newsitemid=20241120268759&amp;lan=en-US&amp;anchor=tubeless+insulin+pump&amp;index=1&amp;md5=807c8b95f30f75f117e9943595c99975">tubeless insulin pump</a> technology with its Omnipod&#xAE; brand of products, today announced the Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott's FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This makes Omnipod 5 the most connected tubeless AID system in the U.S.

PODD

Insulet Announces Omnipod 5 System Is Now Compatible With Abbott's FreeStyle Libre 2 Plus Sensor In The U.S.

<a href="https://abbott.mediaroom.com/press-releases?item=124678" title="https://abbott.mediaroom.com/press-releases?item=124678">https://abbott.mediaroom.com/press-releases?item=124678</a>

Abbott's Amplatzer Amulet Device Demonstrates Superior Long-Term Stroke Prevention And Reduced Blood-Thinner Use In AFib Patients Compared To Watchman; Five-Year Data Presented At AHA 2024 And Published In JACC

The global plant-based Active Pharmaceutical Ingredient (API) market is projected to grow at a steady pace, reaching a valuation of $52.1 billion by 2034, according to a <a href="https://www.futuremarketinsights.com/reports/plant-based-api-market">new report</a> by Future Market Insights. The industry is expected to expand at a Compound Annual Growth Rate (CAGR) of 5.6%, fueled by rising demand for natural and sustainable pharmaceutical solutions, including <a href="https://www.benzinga.com/markets/psychedelics">psychedelics</a> and <a href="https://www.benzinga.com/topic/cannabis-products">cannabis-derived</a> compounds.
<h3 class="wp-block-heading">Rising Demand For Psychedelic And Cannabis-Based Ingredients</h3>
A significant driver of market growth is the increasing use of psychoactive and plant-derived substances in modern pharmacology. Psychedelics like <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> and cannabinoids such as <a href="https://www.benzinga.com/topic/cbd">CBD</a> and <a href="http://v">THC</a> are gaining attention for their <a href="http://v">therapeutic potential</a> in mental health and oncology. The U.S., a key player in the market, is leveraging biotechnological advances like <a href="https://www.genome.gov/genetics-glossary/CRISPR#:~:text=CRISPR%20(short%20for%20%E2%80%9Cclustered%20regularly,editing%20systems%20found%20in%20bacteria.">CRISPR</a> and synthetic biology to scale production of these high-demand APIs, contributing to a 4.2% CAGR.
"The global shift toward sustainable, plant-based solutions reflects both consumer interest in natural medicine and the pharmaceutical industry's focus on alternative therapies," said Sabyasachi Ghosh, associate VP at Future Market Insights. The market&#8217;s rapid expansion underscores the increasing acceptance of psychedelics and cannabis as mainstream pharmaceutical ingredients.
<h3 class="wp-block-heading">Therapeutic Applications And Key Botanical Sources</h3>
Plant-based APIs are harnessed from well-documented medicinal plants such as cannabis, ginseng, turmeric and cinchona. These natural sources contain bioactive compounds like flavonoids, terpenes and alkaloids, offering various therapeutic benefits. Major applications of plant-based APIs include pain management, anti-inflammatory treatments and oncology therapies.
The incorporation of cannabinoids, particularly CBD and THC, into pharmaceutical formulations is reshaping the landscape of pain and anxiety treatments. Similarly, psychoactive compounds from plants like Syrian rue and Psilocybe mushrooms are being explored for treating mental health disorders like depression and PTSD.
<h3 class="wp-block-heading">Regional Growth And Market Segmentation</h3>
The report highlights robust growth in Asian markets, with India leading at an 8.8% CAGR, followed closely by China (8.7%) and South Korea (8.6%). These regions are investing heavily in agricultural biotechnologies and expanding their capabilities in plant-based pharmaceutical production.
The market segments by product type, covering alkaloids, cannabinoids, <a href="https://www.benzinga.com/markets/cannabis/24/05/39064102/cannabis-terpenes-alleviate-chemo-induced-neuropathic-pain-study-shows-added-benefits-with-morph">terpenes</a>, flavonoids and polyphenols. It also includes API forms like extracts, powders and resins from botanicals such as opium poppy, turmeric, ginseng and cannabis.
<h3 class="wp-block-heading">Competitive Landscape: Psychedelics And Cannabis Companies Lead the Charge</h3>
The plant-based API sector is experiencing intense competition, particularly in the cannabis and psychedelics segments. Companies are rapidly scaling production and forming key partnerships to meet the rising demand for plant-based, pharmaceutical-grade ingredients.
Recent developments include Bright Green Corporation's agreement to supply <a href="https://www.benzinga.com/24/02/37292778/dea-clears-this-nasdaq-traded-plant-touching-firm-to-research-and-produce-schedule-i-and-ii-plant-ba">DEA-approved marijuana</a> extracts and psychedelic compounds to Benuvia Operations. Indena's authorization from Italian regulators to produce pharmaceutical-grade CBD further illustrates the expanding global footprint of cannabis-derived APIs.
Key players in the industry include the Illinois-based Abbott (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), New Mexico&#8217;s Bright Green Corporation, Indena S.p.A., headquartered in Milan, Italy, Alchem International Pvt. Ltd., based in India, Israeli Teva Pharmaceutical Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>); Roquette Frères, based in Lestrem, France; and Sami-Sabinsa Group, based in New Jersey.
<h3 class="wp-block-heading">The Future Of Plant-Based APIs: Sustainable And Psychedelic Solutions</h3>
The growing demand for sustainable, natural treatments will likely position the plant-based API market at the forefront of global healthcare. As pharmaceutical companies continue to explore the therapeutic potential of bioactive compounds from plants, the integration of psychedelics and cannabis-derived APIs is likely to play a pivotal role in shaping the next decade of medicine.
Cover image made with AI

Cannabis

Market Summary

Psychedelics

Global

TEVA

Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids

In the last three months, 15 analysts have published ratings on Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $129.93, a high estimate of $149.00, and a low estimate of $117.00. This upward trend is evident, with the current average reflecting a 4.91% increase from the previous average price target of $123.85.
<img src="https://www.benzinga.com/files/images/story/2024/1730818870_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Abbott Laboratories among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$138.00</td>
<td>$133.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$146.00</td>
<td>$143.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$125.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Anthony Petrone</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$130.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>David Lewis</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$117.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$129.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Suraj Kalia</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Maintains</td>
<td>Hold</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Adam Maeder</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$131.00</td>
<td>-</td>
</tr>
<tr>
<td>Raj Denhoy</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Joanna Wiensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$127.00</td>
<td>$119.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Abbott Laboratories. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Abbott Laboratories compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Abbott Laboratories's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Abbott Laboratories's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Abbott Laboratories analyst ratings.</a>
<h2>Discovering Abbott Laboratories: A Closer Look</h2>
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
<h3>Financial Insights: Abbott Laboratories</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Abbott Laboratories displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 4.85%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Abbott Laboratories's net margin is impressive, surpassing industry averages. With a net margin of 15.48%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.16%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.23%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.38, Abbott Laboratories adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Analyst Ratings For Abbott Laboratories

Barclays analyst Matt Miksic maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and raises the price target from $143 to $149.

Price Target

Barclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $149

Reducing Need For Repeat Procedures By 48% Compared To Balloon Angioplasty; New Data From LIFE-BTK Trial Presented At VIVA 2024
<a href="https://abbott.mediaroom.com/press-releases?item=124676" title="https://abbott.mediaroom.com/press-releases?item=124676">https://abbott.mediaroom.com/press-releases?item=124676</a>

Abbott's Esprit BTK System Shows Sustained Two-Year Benefits For Treating Severe Peripheral Artery Disease Below The Knee

WIIM

Abbott Laboratories shares are trading higher after the company announced it along with Reckitt Benckiser won its first trial in premature-infant formula litigation and is cleared of allegations of hiding bowel disease risks.

Abbott Laboratories and a unit of Reckitt Benckiser Group Plc were cleared by a jury over claims they hid risks their premature-infant formulas can cause a bowel disease that severely sickened a baby boy. It was the companies' first trial win in litigation over the products.
<a href="https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial" title="https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial">https://www.bloomberg.com/news/articles/2024-10-31/abbott-reckitt-unit-cleared-of-liability-in-baby-formula-trial</a>

RBGLY

Reported October 31: Abbott Laboratories And Reckitt Benckiser Win First Trial In Premature-Infant Formula Litigation, Cleared Of Allegations Of Hiding Bowel Disease Risks

Insulet Omnipod 5 insulin system available in five more European countries

AbbVie Has Immense Cash Flow Potential

Boston Scientific Standing Apart As A Rare Med-Tech Growth Story

FDA expected to issue ban on Red Dye no. 3

AIVL: This AI-Powered ETF Still Has To Prove Itself

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insmed (INSM – Research Report), Gilead Sciences (GI...

Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Gilead Sciences (GILD) and Abbott Laboratories (ABT)

The Near-Perfect Dividend Portfolio With 10 Sleep-Well-At-Night Gems

Least shorted S&P 500 stocks in December

Catalyst Watch: Netflix earnings, Monster Beverage event, drug data, and quantum volatility

Welcome to "Sector Spotlight," where The Fly looks at a new industry every week and highlights its happenings. PHARMA SECTOR NEWS:&nbsp;In 2024, dr...

Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations

ABCL

ACCD

AGEN

AIEQ

AIVL

ALTR

ALXO

AMOM

AMZN

ARLUF

CANF

CELH

CGON

CMCSA

DXST

FBGL

FTNT

GILD

GLXZ

GMVHF

GOOG

GOOGL

ILMN

INKT

INSM

INTU

ISRG

ITCI

JSPR

KURA

MMYT

MNST

MSFT

MSTR

MVRK

NFLX

QBTS

QRFT

REGN

RGTI

RHHBY

RHHVF

RLAY

SCHW

SIEGY

SLXN

SMPL

SSNLF

TCHBF

TOPP

TSX:VG

TWLO

WFCNP

Screenshot 2024-12-03 at 7.43.04 PM

GCTK

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

Screenshot 2024-10-03 at 5.30.47 PM

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Press Releases

"Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside to Watch"

"Cardiol Therapeutics (NASDAQ: CRDL) Heart Health Innovation – AVCO, GXAI, UPC, and More Stocks Driving Groundbreaking Advances"

University of Nebraska Wins the Abbott and Big Ten Conference's Nationwide 'We Give Blood Drive' Competition, Receives $1 Million Grant from Abbott

Abbott Increases Quarterly Dividend for 53rd Consecutive Year

Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart

Abbott's FreeStyle Libre® 2 Now Reimbursed for Children and Adults Living with Diabetes in Alberta

Abbott Hosts Conference Call for Fourth-Quarter Earnings

LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

PUBLIC HEALTH ADVOCACY INSTITUTE (PHAI) FILES CLASS ACTION AGAINST ABBOTT LABORATORIES OVER MARKETING OF "TODDLER MILK"

Comments

Abbott Laboratories

ニュース

最新ニュース Abbott Laboratories (NYSE:ABT) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル